A company receives multiple complaints regarding the text included on a recently launched product's label. What action should the regulatory affairs professional take FIRST?
According to the GHTF IVD guidance, which of the following is the CORRECT classification for a blood glucose self-testing kit?
Which question is pertinent to demonstrate a new pharmaceutical's effectiveness during evaluation by a reimbursement agency?
What are the MOST important elements that global regulatory agencies want to know before approving a new product for sale in their countries?